{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-041333","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2026-09-03T15:45:15+00:00","discovered_at":"2026-09-03T15:46:09.778946+00:00","generated_at":"2026-09-03T15:46:13.472819+00:00","sec_items":["3.03","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"GT Biopharma effects 1-for-25 reverse stock split, cuts authorized shares to 26.5M","bullets":["Reverse split effective 12:01 a.m. ET Sept 8, 2026; trading on split-adjusted basis begins at market open.","Outstanding shares drop from ~45,109,497 to ~1,804,379; no fractional shares, cash paid for fractions.","Authorized capital reduced from 265M to 26.5M shares (25M common, 1.5M preferred); new CUSIP 36254L407.","Certificates of Elimination filed for Series A-K preferred; all Series C converted, no other preferred outstanding.","Board approved 1-for-25 ratio on Aug 27, 2026, following stockholder authorization at Aug 14 meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-041333","json":"https://secwatch.observer/filing/0001493152-26-041333.json","markdown":"https://secwatch.observer/filing/0001493152-26-041333.md","text":"https://secwatch.observer/filing/0001493152-26-041333.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000149315226041333/0001493152-26-041333-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000149315226041333/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-03T15:46:13.472819+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}